These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34496804)

  • 1. Tuberculosis screening costs and cost-effectiveness in high-risk groups: a systematic review.
    Alsdurf H; Empringham B; Miller C; Zwerling A
    BMC Infect Dis; 2021 Sep; 21(1):935. PubMed ID: 34496804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How much does TB screening cost? A systematic review of economic evaluations.
    Empringham B; Alsdurf H; Miller C; Zwerling A
    Int J Tuberc Lung Dis; 2022 Jan; 26(1):38-43. PubMed ID: 34969427
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.
    Uppal A; Rahman S; Campbell JR; Oxlade O; Menzies D
    PLoS Med; 2021 Sep; 18(9):e1003712. PubMed ID: 34520463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area.
    Li J; Yip BHK; Leung C; Chung W; Kwok KO; Chan EYY; Yeoh E; Chung P
    PLoS One; 2018; 13(1):e0189531. PubMed ID: 29293514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of adding tuberculosis household contact investigation on passive case-finding strategy in Southwestern Uganda.
    Odongo D; Omech B; Acanga A
    PLoS One; 2023; 18(12):e0288761. PubMed ID: 38127969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active Tuberculosis Screening via a Mobile Health App in Myanmar: Incremental Cost-Effectiveness Evaluation.
    Htet KKK; Phyu AN; Zayar NN; Chongsuvivatwong V
    JMIR Form Res; 2023 Nov; 7():e51998. PubMed ID: 37948119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis.
    Silke F; Earl L; Hsu J; Janko MM; Joffe J; Memetova A; Michael D; Zheng P; Aravkin A; Murray CJL; Weaver MR
    Lancet Glob Health; 2024 Jul; 12(7):e1159-e1173. PubMed ID: 38876762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics.
    Adelman MW; McFarland DA; Tsegaye M; Aseffa A; Kempker RR; Blumberg HM
    Open Forum Infect Dis; 2018 Jan; 5(1):ofx269. PubMed ID: 29399596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
    Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
    Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis.
    Brümmer LE; Thompson RR; Malhotra A; Shrestha S; Kendall EA; Andrews JR; Phillips P; Nahid P; Cattamanchi A; Marx FM; Denkinger CM; Dowdy DW
    Clin Infect Dis; 2024 Jan; 78(1):154-163. PubMed ID: 37623745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia.
    Jo Y; Kagujje M; Johnson K; Dowdy D; Hangoma P; Chiliukutu L; Muyoyeta M; Sohn H
    PLoS One; 2021; 16(9):e0256531. PubMed ID: 34499668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of active tuberculosis screening among high-risk populations in low tuberculosis incidence countries: a systematic review, 2008 to 2023.
    Gogichadze N; Sagrera A; Vicente JÁ; Millet JP; López-Seguí F; Vilaplana C
    Euro Surveill; 2024 Mar; 29(12):. PubMed ID: 38516785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence.
    Currie CS; Floyd K; Williams BG; Dye C
    BMC Public Health; 2005 Dec; 5():130. PubMed ID: 16343345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.
    Diel R; Lampenius N; Nienhaus A
    Pharmacoeconomics; 2015 Aug; 33(8):783-809. PubMed ID: 25774015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of community active case finding and household contact investigation for tuberculosis case detection in urban Africa.
    Sekandi JN; Dobbin K; Oloya J; Okwera A; Whalen CC; Corso PS
    PLoS One; 2015; 10(2):e0117009. PubMed ID: 25658592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.